Preliminary results of a phase I/II study involving natural killer chimeric antigen receptor (CAR-NK) therapy for treatment of relapsed non-Hodgkin lymphomas and chronic lymphocytic leukemia.
Home / Resource Library / Phase I-II clinical trial with CAR-NK cells against CD19-positive non-Hodgkin lymphoma or chronic lymphocytic leukemia